The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1.

[1]  S. Anker,et al.  Superiority of endothelin-1 over norepinephrine in exercise-induced alterations of the conduit artery tone of the non-exercised arm in patients with chronic heart failure. , 2000, International journal of cardiology.

[2]  Julie H. Campbell,et al.  J. Submicrosc. Cytol. Pathol. , 2000 .

[3]  K. Münter,et al.  Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[4]  L. Mestroni,et al.  Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. , 1999, Journal of the American College of Cardiology.

[5]  B. Bozkurt,et al.  Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. , 1999, Circulation.

[6]  J. Thornby,et al.  Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. , 1999, Journal of the American College of Cardiology.

[7]  Josef Niebauer,et al.  Endotoxin and immune activation in chronic heart failure: a prospective cohort study , 1999, The Lancet.

[8]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[9]  L. Moreland.  Inhibitors of tumor necrosis factor for rheumatoid arthritis. , 1999, The Journal of rheumatology. Supplement.

[10]  S. Anker,et al.  Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. , 1999, Current opinion in cardiology.

[11]  P. Ponikowski,et al.  Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. , 1999, European heart journal.

[12]  R. von Harsdorf,et al.  Superoxide induces apoptosis in cardiomyocytes, but proliferation and expression of transforming growth factor‐β1 in cardiac fibroblasts , 1999, FEBS letters.

[13]  A. Matsumori,et al.  Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. , 1999, Journal of the American College of Cardiology.

[14]  S. Ertel,et al.  Endothelin antagonism with bosentan: a review of potential applications , 1999, Journal of Molecular Medicine.

[15]  G. Schuler,et al.  Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. , 1999, Journal of the American College of Cardiology.

[16]  M. Böhm,et al.  Effects of endotoxin on human myocardial contractility involvement of nitric oxide and peroxynitrite. , 1999, Journal of the American College of Cardiology.

[17]  S. Anker,et al.  Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. , 1999, Chest.

[18]  S. Anker,et al.  Loss of bone mineral in patients with cachexia due to chronic heart failure. , 1999, The American journal of cardiology.

[19]  M. Lohse,et al.  Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. , 1999, Circulation.

[20]  S. Frøland,et al.  Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1999, The American journal of cardiology.

[21]  B. Combe,et al.  Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. , 1999, The Journal of rheumatology.

[22]  M. Goldenberg,et al.  Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. , 1999, Clinical therapeutics.

[23]  H. Drexler,et al.  Endothelial dysfunction in human disease. , 1999, Journal of molecular and cellular cardiology.

[24]  G. Schuler,et al.  Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. , 1999, Journal of the American College of Cardiology.

[25]  V. Palace,et al.  The role of oxidative stress in the genesis of heart disease. , 1998, Cardiovascular research.

[26]  P. Poole‐Wilson,et al.  Uric acid in chronic heart failure: a marker of chronic inflammation. , 1998, European heart journal.

[27]  D. Sawyer,et al.  Nitric oxide in the failing myocardium. , 1998, Cardiology clinics.

[28]  S. Anker,et al.  Uric acid in chronic heart failure: a measure of the anaerobic threshold. , 1998, Metabolism: clinical and experimental.

[29]  G. Sanz,et al.  Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. , 1998, The American journal of cardiology.

[30]  D. Webb,et al.  Endothelin as a regulator of cardiovascular function in health and disease , 1998, Journal of hypertension.

[31]  H. Drexler,et al.  Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. , 1998, European heart journal.

[32]  S. Anker,et al.  Catecholamine levels and treatment in chronic heart failure. , 1998, European heart journal.

[33]  D. Harrison,et al.  Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. , 1998, Journal of molecular and cellular cardiology.

[34]  H. Volk,et al.  Systemic inflammation in patients with heart failure. , 1998, European heart journal.

[35]  W. Paulus,et al.  Pro-inflammatory cytokines and endothelium-dependent vasodilation in the forearm. Serial assessment in patients with congestive heart failure. , 1998, European heart journal.

[36]  F. Clubb,et al.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.

[37]  K. Sliwa,et al.  Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy , 1998, The Lancet.

[38]  D. Mann,et al.  Differential expression of heat shock proteins in normal and failing human hearts. , 1998, Journal of molecular and cellular cardiology.

[39]  S. Frøland,et al.  Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. , 1998, The American journal of cardiology.

[40]  P. Poole‐Wilson,et al.  Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. , 1998, QJM : monthly journal of the Association of Physicians.

[41]  H. Figulla,et al.  Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy. , 1998, International journal of cardiology.

[42]  C. Holt,et al.  Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. , 1998, Journal of molecular and cellular cardiology.

[43]  D. Fukai,et al.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.

[44]  M. Creager,et al.  Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. , 1998, Circulation.

[45]  G. Feuerstein,et al.  Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. , 1998, Journal of cardiovascular pharmacology.

[46]  E. Oechslin,et al.  Endothelial control of vascular tone in chronic heart failure. , 1998, Journal of Cardiovascular Pharmacology.

[47]  T. Imaizumi,et al.  Oxidative stress is related to exercise intolerance in patients with heart failure. , 1998, American heart journal.

[48]  H. Kan,et al.  Effects of cytokines and nitric oxide on myocardial E-C coupling , 1998, Basic Research in Cardiology.

[49]  C. Thiemermann,et al.  Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone. , 1997, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[50]  L. Lind,et al.  Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease , 1997, Journal of internal medicine.

[51]  S. Anker,et al.  Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. , 1997, Journal of the American College of Cardiology.

[52]  S. Yusuf,et al.  Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. , 1997, The Canadian journal of cardiology.

[53]  K. Pulkki,et al.  Cytokines and cardiomyocyte death. , 1997, Annals of medicine.

[54]  H. Oral,et al.  Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. , 1997, Circulation research.

[55]  K. Wasserman,et al.  Nitric oxide production during exercise in chronic heart failure. , 1997, American heart journal.

[56]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[57]  S. Anker,et al.  Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. , 1997, Heart.

[58]  P. Poole‐Wilson,et al.  Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.

[59]  S. Huber.  Autoimmunity in myocarditis: relevance of animal models. , 1997, Clinical immunology and immunopathology.

[60]  D. Mann,et al.  The role of cytokines in disease progression in heart failure. , 1997, Current opinion in cardiology.

[61]  S. Anker,et al.  Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. , 1997, European heart journal.

[62]  G. Wallukat,et al.  Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. , 1997, Circulation.

[63]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[64]  J. Schaper,et al.  Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. , 1997, European heart journal.

[65]  D. Zechner,et al.  Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. , 1996, The Journal of clinical investigation.

[66]  A. Matsumori,et al.  Immunomodulation: a new horizon for medical treatment of heart failure. , 1996, Journal of cardiac failure.

[67]  D. Mann.  Stress activated cytokines and the heart. , 1996, Cytokine & growth factor reviews.

[68]  D. Harrison,et al.  Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. , 1996, The Journal of clinical investigation.

[69]  Y. Sugishita,et al.  Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. , 1996, Journal of the American College of Cardiology.

[70]  W. Mckenna,et al.  Increased frequency of organ‐specific cardiac antibodies in healthy relatives of patients with dilated cardiomyopathy: Evidence for autoimmunity in polish families , 1996, Clinical cardiology.

[71]  R. Maier,et al.  OXIDANTS AUGMENT ENDOTOXIN‐INDUCED ACTIVATION OF ALVEOLAR MACROPHAGES , 1996, Shock.

[72]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[73]  M. Munger,et al.  Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1996, The American journal of cardiology.

[74]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[75]  E. Rimm,et al.  Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. , 1996, JAMA.

[76]  S. Yusuf,et al.  The Antioxidant Vitamins and Cardiovascular Disease: A Critical Review of Epidemiologic and Clinical Trial Data , 1995, Annals of Internal Medicine.

[77]  A. Matsumori,et al.  Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments. , 1995, European heart journal.

[78]  H. Drexler,et al.  Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. , 1995, The American journal of cardiology.

[79]  D. Fukai,et al.  Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. , 1995, The American journal of cardiology.

[80]  P. Hunziker,et al.  Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.

[81]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[82]  D. Mann,et al.  Expression and functional significance of tumor necrosis factor receptors in human myocardium. , 1995, Circulation.

[83]  D. Mann,et al.  Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. , 1995, The Journal of clinical investigation.

[84]  U. Ikeda,et al.  Nitric oxide synthesis in cardiac myocytes and fibroblasts by inflammatory cytokines. , 1995, Cardiovascular research.

[85]  D. Mann,et al.  Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro. , 1995, The American journal of physiology.

[86]  E. Topol,et al.  Cell adhesion molecules in coronary artery disease. , 1994, Journal of the American College of Cardiology.

[87]  D. Latchman,et al.  Heat Shock Proteins hsp90 and hsp70 Protect Neuronal Cells from Thermal Stress but Not from Programmed Cell Death , 1994, Journal of neurochemistry.

[88]  K. Peuhkurinen,et al.  Myocardial Release of Malondialdehyde and Purine Compounds During Coronary Bypass Surgery , 1994, Circulation.

[89]  M. Kinoshita,et al.  Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. , 1994, Journal of the American College of Cardiology.

[90]  W. Edwards,et al.  Endothelin in human congestive heart failure. , 1994, Circulation.

[91]  S Sasayama,et al.  Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. , 1994, Circulation.

[92]  M. Bevilacqua,et al.  Endothelial-leukocyte adhesion molecules in human disease. , 1994, Annual review of medicine.

[93]  A. Gearing,et al.  Circulating adhesion molecules in disease. , 1993, Immunology today.

[94]  J. Albina,et al.  Nitric oxide-mediated apoptosis in murine peritoneal macrophages. , 1993, Journal of immunology.

[95]  A. Maisel,et al.  Immune function in patients with chronic stable congestive heart failure. , 1993, American heart journal.

[96]  Z. Samra,et al.  Subcellular distribution of xanthine oxidase during cardiac ischemia and reperfusion: an immunocytochemical study. , 1993, Journal of submicroscopic cytology and pathology.

[97]  E. Verrier,et al.  Potential Role of Neutrophil Anti‐Adhesion Therapy in Myocardial Stunning, Myocardial Infarction, and Organ Dysfunction After Cardiopulmonary Bypass , 1993, Journal of cardiac surgery.

[98]  W. Sluiter,et al.  Leukocyte adhesion molecules on the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. , 1993, Journal of cardiovascular pharmacology.

[99]  K. Messmer,et al.  Microvascular ischemia-reperfusion injury in striated muscle: significance of "reflow paradox". , 1992, The American journal of physiology.

[100]  J. Repine,et al.  Hypoxia injures endothelial cells by increasing endogenous xanthine oxidase activity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[101]  P. Merlet,et al.  Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[102]  T. Fahey,et al.  Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. , 1990, The Journal of clinical investigation.

[103]  R. Cotran,et al.  The role of endothelial cells in inflammation. , 1990, Transplantation.

[104]  T. Suzuki,et al.  T‐Lymphocyte subsets as noninvasive markers of cardiomyopathy , 1990, Clinical cardiology.

[105]  W. Abelmann,et al.  In vivo significance of T cells in the development of Coxsackievirus B3 myocarditis in mice. Immature but antigen-specific T cells aggravate cardiac injury. , 1990, Circulation research.

[106]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[107]  M. Grisham,et al.  Leukocyte adherence to venular endothelium during ischemia-reperfusion. , 1989, The American journal of physiology.

[108]  G. Schreiner,et al.  Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[109]  J. Kovacs,et al.  The cardiovascular response of normal humans to the administration of endotoxin. , 1989, The New England journal of medicine.

[110]  W. Roth,et al.  Cardiovascular Effects and Plasma Level Profile of Pimobendan (UD‐CG 115 BS) and Its Metabolite UD‐CG 212 in Patients with Congestive Heart Failure After Single and Repeated Oral Dosing , 1989, Journal of cardiovascular pharmacology.

[111]  K. Bailey,et al.  T-lymphocyte subsets in patients with idiopathic dilated cardiomyopathy. , 1989, International Journal of Cardiology.

[112]  G. Lutty,et al.  Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[113]  R. Bernard,et al.  Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. , 1988, Chest.

[114]  R. Bernard,et al.  Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. , 1988, British journal of clinical pharmacology.

[115]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[116]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[117]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.

[118]  R. Zelis,et al.  Alterations in vasomotor tone in congestive heart failure. , 1982, Progress in cardiovascular diseases.

[119]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.